Land: Sverige
Språk: svenska
Källa: Läkemedelsverket (Medical Products Agency)
alprazolam
2care4 ApS
N05BA12
alprazolam
2 mg
Depottablett
alprazolam 2 mg Aktiv substans; laktosmonohydrat Hjälpämne
Apotek
Receptbelagt
Alprazolam
Avregistrerad
2014-01-21
PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER ALPRAZOLAM KRKA 0.5 MG PROLONGED-RELEASE TABLETS ALPRAZOLAM KRKA 1 MG PROLONGED-RELEASE TABLETS ALPRAZOLAM KRKA 2 MG PROLONGED-RELEASE TABLETS alprazolam READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Alprazolam Krka is and what it is used for 2. What you need to know before you take Alprazolam Krka 3. How to take Alprazolam Krka 4. Possible side effects 5. How to store Alprazolam Krka 6. Contents of the pack and other information 1. WHAT ALPRAZOLAM KRKA IS AND WHAT IT IS USED FOR The active ingredient is alprazolam. It belongs to the group of medicines called benzodiazepines (anxiety-relieving medicines). Alprazolam Krka tablets are used in adults for treatment of anxiety symptoms which are severe, disabling or causing the patient great distress. This medicine is for short-term use only. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ALPRAZOLAM KRKA DO NOT TAKE ALPRAZOLAM KRKA IF YOU - are allergic to alprazolam, other benzodiazepines or any of the other ingredients of this medicine (listed in section 6) - have been diagnosed with _myasthenia gravis_ (a disease causing muscle weakness) - suffer from severe respiratory failure - have sleep apnoea syndrome (prolonged transient cessations of breathing during sleep) - suffer from severe liver insufficiency. WARNINGS AND PRECAUTIONS Talk to your doctor before taking Alprazolam Krka tablets, if you - notice that the effect of the tablets will weaken after you have used them several we Läs hela dokumentet
SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Alprazolam Krka 0.5 mg prolonged-release tablets Alprazolam Krka 1 mg prolonged-release tablets Alprazolam Krka 2 mg prolonged-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 0.5 mg alprazolam. Each prolonged-release tablet contains 1 mg alprazolam. Each prolonged-release tablet contains 2 mg alprazolam. Excipient with known effect: 0.5 mg tablets 1 tablets 2 mg tablets Lactose 183.74 mg 183.69 mg 182.93 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release tablet. _0.5 mg:_ greenish-yellow, round, slightly biconvex. _1 mg:_ white, round, slightly biconvex. _2 mg:_ light blue, round, slightly biconvex. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Alprazolam is indicated for short-term symptomatic treatment of anxiety in adults. Alprazolam is only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY If possible, treatment should be started, monitored and finished by the same doctor. Symptomatic treatment of anxiety _:_ Pharmacological therapy of anxiety should always be adjuvant. _ _ Initial dose 0.5 mg once daily, adjusted individually. Maintenance dosage is 0.5–3 mg/day in one or two divided doses. For elderly patients, patients with impaired hepatic or renal function and those sensitive to the sedative effects of the product, the initial and maintenance dose is 0.5 - 1 mg daily. Dosage may be increased gradually where necessary. It is recommended that daily doses greater than 3 mg be taken in two divided doses. In elderly patients, if too high doses are used, confusion can occur. Duration of treatment: Alprazolam should be used in the lowest possible effective dose, for the shortest possible time and for a maximum of 2-4 weeks. The need for continued treatment should be reassessed frequently. Long-term treatment is n Läs hela dokumentet